The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 39 | — | 20.1x | Near average | |
Growth | 20 | -61.9% | 5.6% | Below average | |
Quality | 29 | -8723.1% | 7.6% | Below average | |
Safety | 26 | 2.7x | 0.4x | Below average | |
Capital Return | 90 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Arcturus Therapeutics Holdings Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Arcturus Therapeutics Holdings Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The data shows complete stability in the average price target for ARCT stock at 22.5 dollars over the periods (last 1, 7, 30 days), with a consensus from 7 analysts without any recent upward or downward revisions. This consistency reflects a state of anticipation among analysts, as the target price range remains confined between 20 and 25 dollars, indicating a decrease in Analyst Dispersion and a narrowing gap between optimistic and pessimistic estimates.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.